Physician profile
Paul B Mitchell
NPI 1053354118
$67,018.45
in general payments reported to CMS, 2019-2025
11 companies · $20K in 2025
The $20K reported for 2025 was more than what 90% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,826 · 2020: $4,987 · 2021: $600 · 2022: $3,534 · 2023: $1,849 · 2024: $31K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Travel and Lodging: $8,946 · Food and Beverage: $3,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,125.00 |
| Travel and Lodging | $8,946.25 |
| Food and Beverage | $3,001.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $50,649.51 | 2020-2025 | Miscellaneous, Shoreline Asc, 7d Surgical System |
| Medtronic USA, INC. | $9,097.20 | 2019-2020 | |
| Medtronic, INC. | $4,998.09 | 2021-2024 | Intellis Adaptivestim, Unid_pass, Synchromedii |
| Cerapedics INC. | $500.00 | 2020 | |
| Providence Medical Technology, INC. | $493.18 | 2024-2025 | |
| Si-Bone, INC. | $306.93 | 2021-2024 | |
| Boston Scientific Corporation | $288.25 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Intrinsic Therapeutics | $239.17 | 2025 | Barricaid Acd (Annular Closure Device) |
| Abbott Laboratories | $219.87 | 2021-2025 | Proclaim |
| Nevro Corp. | $190.26 | 2019-2023 | Senza |
| Integra Lifesciences Corporation | $35.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.